Teva settles second Nuvigil patent fight; Alexion's Soliris nabs new orphan status; Novartis dodges punitive damages;

@FiercePharma: Our newest report, now live: The top 10 best-selling diabetes drugs of 2013. Story | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. More | Follow @TracyStaton

@EricPFierce: India's Lupin wants to buy capacity in EU in biosimilars, inhalation drugs to build markets there. News | Follow @EricPFierce

@CarlyHFierce: Expecting hostile suitors, Shire brings in reinforcements. More | Follow @CarlyHFierce

@JustinHFierce: The USDA licenses first vaccine for Porcine Epidemic Diarhea Virus (PEDv), 7mil pigs already dead since outbreak. News | Follow @JustinHFierce

> Teva Pharmaceutical Industries ($TEVA) settled another patent fight over its wakefulness treatment Nuvigil; the deal allows Sandoz, Actavis ($ACT), Lupin and Apotex to launch their copies of the drug beginning in June 2016. Report

> Alexion ($ALXN) nabbed another orphan-drug tag for its rare-disease drug Soliris, this time as a treatment for a neuromuscular disorder myasthenia gravis. Report

> Novartis ($NVS) won't have to pay punitive damages in a lawsuit alleging that the company failed to warn that two of its cancer drugs could cause a bone disorder, a Florida judge ruled. Report

> A U.S. hedge fund has snapped up enough Teva Pharmaceutical Industries ($TEVA) stock to make up 2.66% of its first-quarter portfolio. Report

> Novartis ($NVS) asked a New York judge to toss claims that it violated the False Claims Act by paying kickbacks to pharmacies. Report

Medical Device News

@FierceMedDev: ICYMI: Done deal: Medtronic to buy Covidien for $42.9B. Story | Follow @FierceMedDev

@StacyALawrence: iWatch to unite Apple healthcare strategy? Article | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. More | Follow @MichaelGFierce

@EmilyWFierce: "Strokefinder" microwave helmet could provide a portable, quick way to diagnose strokes in ambulances. News | Follow @EmilyWFierce

> Flurry of M&A deals points to industrywide move to consolidate. More

> Tissue Regenix talks up acquisition after recent product launch. Story

> Edwards gets FDA nod to begin U.S. rollout of its Sapien XT TAVR. Article

Biotech News

@FierceBiotech: Pfizer, Novartis race to market with 'breakthrough' meningitis B vaccines. Story | Follow @FierceBiotech

@JohnCFierce: Selecta ramps up a gout program, gets more cash for vaccine R&D. News | Follow @JohnCFierce

@DamianFierce: As you head home from 2014 ADA, check out FiercePharma's rundown of the best-selling diabetes drugs. More | Follow @DamianFierce

> True North snags $22M and sets course for the clinic with a rare disease drug. More

> Merck KGaA pulls the plug on Ono's MS drug as the market crowds. Article

> GW spikes on positive results for cannabis-based epilepsy drug. Item

Biotech Research News

> UPenn team combats Parkinson's with immunotherapy that targets neuron killers. More

> Party drug ketamine shows potential as rapid-acting therapy for depression. Article

> Copper compound increases survival in mice with ALS. News

> Type 1 diabetes reversed in mice. Item

> Think tank: $4.5B investment in BRAIN project too modest. Report

> NIH would get 2% budget hike under Senate bill. More

Pharma Manufacturing News

> Health Canada lets Biolyse restore production of paclitaxel. News

> OSHA fines a Wisconsin API maker that no longer exists almost half a million. More

> FDA approves Novartis U.S. vaccine plant it is trying to sell. Article

> India's Lupin ready to spend $1B to bulk up in EU. Story

> Grand River Aseptic Manufacturing gets $9.8M boost. Report

> FDA says Apotex India plant has faked data for years. Item

And Finally... Diet and exercise are better than the diabetes drug standby metformin at holding off the disease in people at risk. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.